HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial

The use of the HeartWare pump as a bridge to transplant continues to demonstrate a high 180-day survival rate despite a low rate of transplant. Adverse event rates are similar or better than those observed in historical bridge-to-transplant trials, despite longer exposure times due to longer survival and lower transplant rates.